Strides Pharma receives EIR for Bengaluru facility from USFDA

Our Bureau Mumbai | Updated on March 30, 2020 Published on March 30, 2020

Strides Pharma Science Ltd logo   -  Website/strides


Strides Pharma Science Ltd has received Establishment Inspection Report (EIR) for the inspection conducted by the US Food and Drug Administration (USFDA) in January 2020 at KRS Gardens, Bengaluru.

The inspection was related to specific extended-release applications made from the site, and the receipt of EIR confirms the successful closure of the inspections, the company said in a statement.


KRS Gardens, the company’s flagship facility in Bengaluru is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids. The facility is also capable of manufacturing complex formulations of extended-release tablets.

Strides have a large extended-release portfolio for the US and other regulated markets with a capability to manufacture these products at multiple sites, it added.

Strides had recently received EIR for the Bengaluru facility from USFDA for the inspection conducted in March 2020.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on March 30, 2020
This article is closed for comments.
Please Email the Editor